The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway

• Auteurs principaux: Shuhan Liu (Auteur), Shengxiang Wang (Auteur), Runze Gu (Auteur), Na Che (Auteur), Jing Wang (Auteur), Jinbo Cheng (Auteur), Zengqiang Yuan (Auteur), Yong Cheng (Auteur), Yajin Liao (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Exportin 1 (XPO1) is an important transport receptor that mediates the nuclear export of various proteins and RNA. KPT-8602 is a second-generation inhibitor of XPO1, demonstrating the lowest level of side effects, and is currently in clinical trials for the treatment of cancers. Previous studies sug...